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Abstract 
 
The old herbal drug aristolochic acid (AA), derived from Aristolochia species has been 
associated with the development of a novel nephropathy, designated as aristolochic acid 
nephropathy (AAN), and human urothelial cancer. The major components of the plant extract 
AA are nitrophenanthrene carboxylic acids, which are genotoxic mutagens after metabolic 
activation. The major activation pathway involves reduction of the nitro group primarily 
catalysed by NAD(P)H:quinone oxidoreductase to an electrophilic cyclic N-acylnitreniumion 
that reacts preferentially with purine bases to form covalent DNA adducts. These specific 
AA-DNA adducts have been identified and detected in experimental animals exposed to AA 
or botanical products containing AA, and in urothelial tissues from AAN patients. In rodent 
tumours induced by AA the predominantly formed DNA adduct 7-(deoxyadenosin-N6-
yl)aristolactam I has been associated with the activation of ras oncogenes through a 
characteristic transversion mutation. Such A:T→T:A mutations have been identified in the 
p53 gene of urothelial tumours of a patient with AAN and in several patients suffering from 
Balkan endemic nephropathy (BEN) along with specific AA-DNA adducts. This is a rare 
example of a human cancer causally linked to a distinct environmental exposure (use of a 
herbal product), where the carcinogenic process of initiation is well-established linking 
formation of carcinogen-specific exposure (specific DNA adduct formation) with the presence 
of characteristic human tumour mutations.  
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Abbreviations 
 
AA, aristolochic acid; AAN, aristolochic acid nephropathy; BEN, Balkan endemic 
nephropathy; CHN, Chinese herbs nephropathy; CYP, cytochrome P450; dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; dA-
AAII, 7-(deoxyadenosin-N6-yl)aristolactam II; NQO1, NAD(P)H:quinone oxidoreductase;  
 
Introduction 
 
This review discusses the molecular mechanism of the herbal product aristolochic acid (AA) 
leading to cancer in experimental animals and humans. These mechanistic investigations 
gathered from 1986 to present contributed that herbal remedies containing plant species of the 
genus Aristolochia were classified as carcinogenic to humans (Group 1) by the International 
Agency for Research on Cancer (IARC) [1] and that the National Toxicology Program (NTP) 
considers AA as a substance known to be a human carcinogen [2]. 
AA, the principal extract of Aristolochia species is a mixture of structurally related 
nitrophenanthrene carboxylic acids, the major components being aristolochic acid I (AAI) and 
aristolochic acid II (AAII) (Figure 1). AA is found in plants of both the Aristolochia and 
Asarum genera of the family Aristolochiaceae. Herbal drugs derived from Aristolochia 
species have been used since antiquity in obstetrics and in the treatment of snake bite, 
festering wounds, and tumours, and they remain in use today, particularly in Chinese herbal 
medicine [1]. All parts of the plant are used for herbal remedies, and AA is present in roots, 
stems, leaves, and fruit. In the 1970s the anti-inflammatory properties of AA encouraged the 
development of pharmaceutical preparations in Germany until Mengs and coworkers showed 
that AA is a strong carcinogen in rats [3]. Subsequently, AA was found to be a genotoxic 
mutagen and all pharmaceutical preparations containing AA were withdrawn from the market 
in Germany and in many other countries. However, Aristolochia plants are still used in 
traditional medicine in some parts of the world [4].  
So-called Chinese herbs nephropathy (CHN), a unique type of rapidly progressive renal 
fibrosis, was first reported in Belgian women who had consumed Chinese herbs as part of a 
wheight-loss regimen in 1991 [●5]. So far over 100 CHN cases have been identified in 
Belgium [4]. The observed nephrotoxicity has been traced to the ingestion of Aristolochia 
fangchi inadvertently included in the slimming pills [6].  
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Exposure to AA was demonstrated by the identification of specific AA-DNA adducts in 
urothelial tissue of these CHN patients using a highly sensitive detection method (32P-
postlabelling method) [●7-9]. Within a few years CHN patients developed a high risk of 
urothelial cancer; urothelial malignancy of the upper urinary tract arose in almost half of the 
patients [●●9]. According to the review by Debelle and colleagues [4] in 2008 CHN has been 
described in patients in other European (Germany, UK, France, Spain) and in Asian countries 
(China, Taiwan, Japan, Korea) and in the USA (about 170 cases), who had been exposed to 
Aristolochia species containing AA and had no relationship with the Belgian cohort. 
Therefore, it has been proposed to designate this novel interstitial nephropathy in which the 
unequivocal role of AA has been fully documented as aristolochic acid nephropathy (AAN) 
[10]. Since more and more AAN cases are reported world-wide and all are related to exposure 
to AA, it is of great concern that this form of nephropathy and associated urothelial cancers may 
occur more commonly in the future [4]. As a consequence products containing AA have been 
banned in many countries world-wide and consumers have been advised to discontinue 
immediately the use of any botanical products containing AA (Food and Drug Administration 
consumer advisory, 2001). However, despite warnings, a number of herbal products 
containing Aristolochia species continue to be advertised for sale on the internet [4]. 
The intention of this review is to summarize data on the genotoxic mechanism of AA 
carcinogenicity in animals and humans. The pathogenesis of the AA nephropathy has been 
reviewed recently by Debelle colleagues [4]. 
 
Carcinogenic mechanism of aristolochic acid in animals 
Carcinogenicity in animals 
The natural mixture AA is a strong carcinogen in rats [1, 3]. Main targets for AA-induced 
carcinogenicity were forestomach, kidney and urinary tract. AA is also a potent carcinogen in 
mice after oral treatment and in rabbits after intraperitoneal injections. Most studies 
administered a mixture of aristolochic acids I and II; however, similar carcinogenic effects 
were also observed with pure aristolochic acid I [11, 12]. Moreover, complete extracts from 
Aristolochia species (decoctions from A. manshuriensis and an aqueous extract of A. fructus), 
when administered orally to rats induced tumours of the forestomach and the kidney [13, 14]. 
Squamous-cell carcinomas were found in the forestomach of male rats treated with the 
weight-loss regimen of herbal ingredients that contained AA used in the Belgian slimming 
clinic [15] demonstating that the plant material ingested by AAN patients is able to induce 
tumour formation. 
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Metabolism of AA 
The metabolism of AA has been studied in different species including man and has shown 
that products of nitroreduction, the corresponding aristolactams, are the major metabolites 
found in urine and faeces [16]. Other minor metabolites formed through O-demethylation and 
denitration have also been reported. In humans the aristolactams I and II were the only 
metabolites detected in urine although full metabolic profiles have not been reported. Phase II 
metabolites of aristolochic acids were found in the urine of rats and include N- and O-
glucuronides, O-acetates and sulfate esters [17]. 
 
Metabolic activation of AA and DNA adduct formation 
First hints on the mode of action of the rodent carcinogen AA came from studies in bacteria. 
AAI and AAII are direct mutagens in the Salmonella strains TA100 and TA1537 but were 
only weakly mutagenic in the strains lacking the classical bacterial nitroreductase [18]. Using 
genetically engineered YG strains Götzl and Schimmer [19] confirmed that only the nitro 
group is important for the mutagenic activity of AA in Salmonella. Nevertheless both AAs are 
only weak mutagens in the Ames assay (less than 1 revertant per nanomole) when compared 
to other nitroaromatic compounds [20].  
A powerful tool of elucidating the pathway of activation of carcinogens is to identify and 
quantify the DNA adducts it forms, and to determine what factors modulate adduct formation. 
This approach was successfully applied and demonstrated that AA is a genotoxic mutagen 
after metabolic activation. For the detection of DNA adduct formation by AA in vitro and in 
vivo the 32P-postlabelling assay was used, all AA-DNA adduct analyses reported were 
performed by this assay almost exclusively [21]. 
The 32P-postlabelling assay is an ultrasensitve method for the detection and quantitation of 
carcinogen-DNA adducts [22]. It consists of 4 steps: (i) enzymatic digestion of DNA to 
nucleoside 3’-monophosphates; (ii) enrichment of the adduct fraction of the digest; (iii) 5’-
labelling of the adducts with 32P-orthophosphate; (iv) finally the labelled adducts are 
subjected to chromatographic separation, to generate a profile of adducts that can be 
visualized and quantified by measurement of their radioactive decay. The assay requires only 
microgram quantities of DNA and is capable of detecting adducts at frequencies as low as 1 in 
109 normal nucleotides. 
Using the 32P-postlabelling assay characteristic maps on thin layer plates were obtained when 
DNA isolated from organs of animals treated by AA was analysed. These chromatograms 
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showed several distinctive adduct spots grouped as a specific spot pattern depending on the 
treatment. Treatment of rats by AAI resulted in the formation of three DNA adduct spots in 
forestomach DNA when analysed by the 32P-postlabelling method with enrichment by 
nuclease P1 digestion. In contrast after AAII-treatment two AA-DNA adducts were detected 
and the mixture AA showed a combination of adduct patterns of the main components. Such a 
characteristic spot pattern can be used as a fingerprint left by AA on DNA to monitor 
exposure to animals and humans. Numerous studies using the 32P-postlabelling method have 
shown that AA or the pure major components AAI or AAII form specific DNA adducts in 
several organs of treated rodents confirming that the chemical carcinogen AA acts by a 
genotoxic mechanism in vivo [1]. 
Three of the four AA-DNA adducts were identified by comparison with structurally identified 
synthetic adducts prepared by reductive activation of AAI and AAII as 7-(deoxyadenosin-N6-
yl)aristolactam I (dA-AAI), 7-(deoxyguanosin-N2-yl)aristolactam I (dG-AAI) and 7-
(deoxyadenosin-N6-yl)aristolactam II (dA-AAII) [21] (Figure 2) and assigned to the adduct 
spots as shown in Figure 3. The dA-AAII adduct is formed from AAII but also from AAI 
through a demethoxylation reaction. A second deoxyguanosine adduct formed by reaction of 
AAII with deoxyguanosine 3’-monophosphate and DNA was tentatively assigned as 7-
(deoxyguanosin-N2-yl)aristolactam II (dG-AAII) [21]. These chemical structures indicate that 
a cyclic N-acylnitrenium ion with a delocalised positive charge (aristololactam-nitreniumion) 
as the ultimate electrophilic species binds preferentially to the exocyclic amino groups of 
purine nucleotides in DNA through the C-7 position of the phenanthrene ring (Figure 2). 
Recently the structures of the purine AA-DNA adducts were confirmed by mass spectrometry 
along with AA-adducts bound to the exocyclic amino group of cytosine [23]. These AA-
deoxycytidine adducts formed in in-vitro reactions with reductively activated AAI and AAII 
and DNA exhibited the same imino characteristics as shown before by NMR for the 
deoxyadenosine AA-adducts. However, AA-deoxycytidine DNA adducts have never been 
detected in in-vivo studies. This preference of AA for reaction with the exocyclic amino group 
of DNA bases is unusual for nitroaromatic compounds since their ultimate carcinogenic 
species is a nitrenium ion whose major target site in DNA is the C-8 atom of guanine. 
It is well known that conjugation reactions like acetylation catalysed by phase II enzymes are 
important in the metabolic activation of carcinogenic nitroaromatics and aromatic amines. 
Concerning the activation of AA phase II reactions do not seem to play a role. Instead the 
formation of a cyclic hydroxamic acid (N-hydroxylactam) favoured by the carboxy group in 
peri position to the nitro group represents a unique example for an intra-molecular 
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conjugation (acylation), which leads to the ultimate carcinogen. Recently the N-
hydroxylactam was detected in the urine of AA-treated rats confirming its formation during 
AA metabolism [23]. 
The enzymatic activation of AA was extensively studied using DNA binding as a probe for 
metabolic activation and has been reviewed by Stiborova and co-workers [16]. The major 
activation pathway, reduction of the nitro group is catalysed by a number of cytosolic and 
microsomal enzymes, cytosolic NAD(P)H:quinone oxidoreductase (NQO1) being the most 
efficient [24]. In hepatic microsomes reductive activation of AA was attributed to cytochrome 
P450 (CYP) 1A1 and CYP1A2. Another AA-activating enzyme is prostaglandin H synthase 
(cyclooxygenase, COX), which is highly expressed in urothelial tissue. Both AAs when 
activated by these different enzymatic systems produced AA-specific DNA adduct patterns 
similar to that obtained in vivo, confirming that nitroreduction is the crucial step in the 
pathway of metabolic activation of AA to their ultimate DNA binding species. No oxidative 
activation of AA has been reported, yet. However, the aristolactams, the principal metabolites 
of AA (Figure 2) are activated oxidatively forming the same DNA adducts as AA after 
reductive activation. Although the fraction of adducts produced by the aristolactams 
contributing to total AA-DNA adduct formation has not been determined it seems not to be 
significant. In fact, Dong and co-workers [25] found only low amounts of dA-AAI and dG-
AAI adducts (50 times lower than that observed with AAI and AAII), with the highest levels 
in the target tissue, renal pelvis, in Wistar rats treated with aristolactam I. 
 
Mutations induced by AA 
Protooncogenes have been identified as genetic targets that are involved in chemical 
carcinogenesis. In rodents many chemical carcinogens activate the ras protooncogene by a 
single point mutation in codons 12, 13 or 61. Likewise, AA-initiated carcinogenesis in rodents 
is associated with the activation of H-ras by a specific AT→TA transversion mutation in 
codon 61 (CAA). This mutation occurs exclusively at the first adenine of codon 61 in all 
forestomach and ear duct tumours of rats treated with AAI [11]. The same ras mutation was 
detected in tumours of mice [26] and in forestomach tissue of rats treated with the plant 
extract AA [27]. AT→TA transversions are also the predominant mutations detected in 
reporter genes in AA-treated transgenic mice and rats along with an increased mutation 
frequency in the target organ [28-30].  
This selectivity of AA for mutations at adenine residues is consistent with the extensive 
formation of adenine adducts and a higher persistence of them in comparison to guanine 
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adducts in target organs [31]. Moreover, the translesional bypass of adenine adducts of AA 
(e.g. dA-AAI) observed in primed DNA replication reactions containing oligonucleotides 
with defined AA-DNA adducts placed at specific sites points to a mutagenic potential 
resulting from incorporation of adenine opposite the adduct during DNA replication [32], 
indicating that an AT→TA transversion would be the mutagenic consequence.  
Our postulated mechanism for the carcinogenicity of AA in rats is summarized in Figure 4. 
 
Carcinogenic mechanism of AA in humans 
Aristolochic acid and urothelial cancer 
The outbreak of AAN in 1993 was associated with the ingestion of Chinese herbal remedies 
prescribed by a single clinic; so far 128 patients with AAN have been identified in Belgium, 
mostly women, half of whom needed renal replacement therapy, mostly including renal 
transplantation [33]. In 1990 this clinic in Brussels began prescribing slimming pills 
consisting of Chinese herbal remedies intended to contain, in part, Stephania tetrandra (for its 
purported diuretic effects). However, it was shown that S. tetrandra (Han Fang-ji) was 
inadvertently replaced by A. fangchi (Guang Fang-ji) presumably because both plants are 
used in Chinese folk medicine under similar names, Fangji [4]. 
AA-DNA adducts were identified in all urothelial tissues available for analysis of Belgian 
AAN patients by 32P-postlabelling (Figure 3A and 3B). By contrast, DNA of kidneys from 
several patients with other renal diseases was virtually free of DNA adducts (Figure 3C). The 
presence of AA-DNA adducts in kidney and ureter demonstrated unambiguously prior 
exposure of these women to AA contained in plant material from A. fangchi [●7, 8, ●●9, 34].  
Within a few years AAN patients developed a high risk of urothelial cancer; urothelial 
malignancy of the upper urinary tract arose in almost half of the patients [●●9]. The 
cumulative dose of A. fangchi was a significant risk factor; patients with an intake of 200 g of 
herbs (the average herbal intake) had a 50% risk of developing cancer. More recently, it was 
found that even patients who do not display the characteristic histological features of AAN 
are also at risk of malignancy [35]. 
This clearly indicates that AA is not only a strong rodent carcinogen but also a potent human 
carcinogen. In the meantime urothelial carcinoma associated with high levels of AA-DNA 
adducts in the urothelial tissue have been reported outside the Belgian cohort, pointing to the 
direct carcinogenic potential of AA in AAN patients [36]. Moreover, the demonstration that 
in rabbits and in rats [4], AA given as single drug causes similar renal interstitial fibrosis as 
 9
well as urothelial tumours as observed in AAN patients removed any doubt on the causal role 
of AA in AAN and AAN-associated urothelial malignancy. 
 
The potential role of AA-DNA adducts in AAN-associated urothelial cancer 
AA-DNA adducts are not only suitable biomarker for exposure to AA, but also they seem to 
play a critical role in the carcinogenic process of AA. In renal and ureteral tissue of AAN 
patients three AA-specific DNA adducts, one major (dA-AAI) and two minor ones (dG-AAI 
and dA-AAII) were identified [●7-10, 34, 36] by the 32P-postlabelling method exhibiting the 
characteristic adduct pattern by thin layer chromatography (Figure 3). Cochromatographic 
analyses using independent separation systems proofed that these are the same AA-DNA 
adducts detected previously in animals exposed to AA with levels ranging from 
approximately 0.1 to 50 adducts per 108 nucleotides. On the other hand no difference was 
found between the levels of AA-DNA adducts in AAN patients with urothelial cancer and 
tumour-free AAN patients [9]. This might be due to the fact that adduct formation is not 
linear with dose at the high amounts of AA that AAN patients had ingested. 
Recently, Grollman and colleagues [●●37] identified AA-DNA adducts in renal tissue of an 
American woman with documented exposure to AA (around 2 adducts per 107 nucleotides) 
using 32P-postlabelling along with an electrophoretic separation of the adducts (32P-
postlabelling/PAGE). More importantly, in this study the adenine adducts of AAI and AAII 
were identified by liquid chromatography electrospray ionization/multistage mass 
spectrometry (LC-ESI/MS/MS) in this individual confirming details of the adduct structures 
and removing any doubt that spots or bands detected in tissues of AAN patients by the 32P-
postlabelling method represent the DNA adducts shown in Figure 2. 
The persistence of AA-DNA adducts in human tissue even many years after cessation of the 
slimming regimen is noteworthy [9]. The most prominent adduct found in all AAN patients 
analysed so far is the dA-AAI adduct. In AA-treated rats irrespective of the tissue analysed 
the dA-AAI adduct is also the predominant adduct. That only the dA-AAI adduct remains in 
urothelial tissues for an extensive period of time (up to 10 years) is consistent with its life-
long persistence in target tissues in rats [31]. Both, the longer persistence and higher initial 
levels of the dA-AAI-adduct in urothelial tissue of AAN patients probably contributed to the 
relative abundance of this adduct.  
More than 50% of all human tumours contain a mutation in p53. In AAN patients urothelial 
atypia were associated with the overexpression of the p53 protein [33], suggesting that p53 is 
mutated in AAN-associated cancer. In deed, in one AAN patient from the UK available for 
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analysis a characteristic AT→TA transversion mutation typical for AA was found in p53 
(exon 5; codon 139 AAG) in urothelial tumour cells [●38]. It is noteworthy that the mutated 
base the first adenine has the same neighbouring bases in codon 138/139 (GCC AAG) of p53 
as in codon 61 (CAA) of H-ras suggesting a sequence-specific mechanism during mutation 
induction. AT→TA transversions also accounted for most of the AA-induced mutations in 
human TP53 knock-in [Hupki] mouse fibroblasts [39, 40] and, interestingly, one of these was 
at the first adenine of codon 139 (AAG) identical to the mutation found in the AAN patient. 
These mutations could trigger tumourigenesis in humans in the same way like mutations in 
codon 61 of H-ras trigger tumourigenesis by AA in rodents and indicate the molecular 
mechanism whereby AA causes urothelial cancer in humans (Figure 4). 
 
Metabolic activation of AA in humans 
The metabolic activation of AA in humans has been reviewed recently by Stiborova and 
colleagues [16] and is comparable to that found in rodents. Most of the activation of AA in 
human hepatic microsomes is mediated by CYP1A2 and, to a lower extent, by CYP1A1. In 
human renal microsomes NADPH:CYP reductase and prostaglandin H synthase 
(cyclooxygenase, COX) are active. The most efficient enzyme in the activation of AA in 
human hepatic and renal cytosols, is like in animals NQO1.  
Around 1500-2000 patients may have been treated in the slimming clinic in Belgium and 
thus, exposed to AA [41]. Therefore the identified AAN cases in Belgium (128) thus 
represent about 5% of the exposed population. Besides differences in the amount of AA 
intake, differences in carcinogen activation could be the reason for this individual 
susceptibility. Indeed, in the human NQO1 gene two polymorphisms have been found in the 
general population and associated with an increased risk for urothelial tumours [42]. 
Remarkably, the frequency of homozygous NQO1*2 mutation varies across ethnic groups and 
was reported to be approximately 5% in Caucasians [43]. 
 
Aristolochic acid and Balkan endemic nephropathy-associated urothelial cancer 
In recent years evidence has accumulated that Balkan endemic nephropathy (BEN) is an 
environmental disease, whose clinical and histopathological features are remarkably similar 
with AAN [44]. That dietary intake of AA may be responsible for BEN and its associated 
urothelial cancer is a theory that was first proposed in 1969 by Ivic and is fully consistent 
with the unique epidemiologic features of BEN. This hypothesis, however, did not receive 
widespread support at the time. However, more recently the same observation was made in 
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endemic regions of Croatia, reviving the old hypothesis that exposure to AA of individuals 
living in endemic areas could occur by dietary intake of bread derived from wheat grain 
which was contaminated with seeds of A. clematitis [45]. 
As earlier proposed by us experimental evidence such as the detection of AA-DNA adducts in 
BEN patients and the identification of AA-specific mutation spectra in tumours of BEN 
patients would establish a strong molecular link between AA and BEN [44]. Indeed, AA-
DNA adducts have been found in two out of three renal tissues collected randomly from 
farmers with upper urinary tract malignancy from areas endemic for BEN, although these 
patients were not classified as clearly suffering from BEN [46]. Recently AT→TA 
transversions have also been reported in patients suffering from BEN along with AA-specific 
DNA adducts [●●37]. In this study mutations at AT pairs accounted for 89% (17/19) of all 
mutations, with the majority of these (15/17; 78%) being AT→TA transversions. Strikingly, 
several TP53 mutations [codons 131 (3×), 209 (3×), 280, 291] found in the urothelial tumours 
from BEN patients were also found in immortalised cells derived from primary human TP53 
knock-in [Hupki] mouse fibroblasts exposed to AA [40]. The frequency and predominance of 
AT→TA transversions may be regarded as a mutational signature for human exposure to AA. 
AA-DNA adducts were detected in all BEN patients with levels of total adducts around 5 
adducts per 107 nucleotides. Such adducts were not detected in renal tissue of patients with 
urothelial cancer who resided in a nonendemic region of Croatia. 
Collectively, these results provide new evidence that AA is a risk factor for BEN and BEN-
associated urothelial cancer and confirm the molecular mechanism of AA carcinogenicity 
shown in Figure 4. However, the role of other factors in the pathogenesis of BEN cannot yet 
be ruled out. 
 
Conclusions 
 
There is increasing evidence that the plant extract AA or/and its major components AAI and 
AAII are responsible for the carcinogenic effects observed in humans who ingested 
Aristolochia plants or herbal medicines prepared from these plants. This conclusion is based 
on sufficient evidence of carcinogenicity in humans and experimental animals, together with 
data on the molecular mechanism demonstrating AAs carcinogenic potential. 
Despite the fact that AA-containing remedies have been banned in several countries, human 
exposure to AA might still occur by usage of traditional herbal remedies. Therefore herbal 
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medicines should be subjected to the same stringent scrutiny and controls as common drugs 
before their release on the market. Owing to the fact that AA is both a powerful nephrotoxin 
and a human carcinogen all botanical-containing products known or suspected of containing 
AA should be banned from the market worldwide. 
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Legends to Figure 
 
Figure 1: Chemical structures of aristolochic acid I (AAI) and II (AAII). 
 
Figure 2: Metabolic activation and DNA adduct formation of aristolochic acid I (AAI) and II 
(AAII); 7-(deoxyadenosin-N6-yl)aristolactam I or II (dA-AAI or dA-AAII), 7-
(deoxyguanosin-N2-yl)aristolactam I or II (dG-AAI or dG-AAII). 
 
Figure 3: Autoradiographic profiles of DNA adducts obtained from DNA of (A) kidney and 
(B) ureter of a patient with aristolochic acid nephropathy (AAN) using the nuclease P1 
enrichment version of the 32P-postlabelling assay. 
 
Figure 4: Postulated mechanism for the carcinogenicity of aristolochic acid in rodents and 
humans. dA-AAI; 7-(deoxyadenosin-N6-yl)aristolactam I. See text for details. 
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